Navigation Links
Turning back the Clock in Inherited Anemias

Reawakening a dormant gene could ease sickle-cell disease and thalassemia

(Vocus) December 4, 2008 -- Researchers at Children's Hospital Boston ( and Dana-Farber Cancer Institute have identified a way to get red blood cells to produce a form of hemoglobin normally made only before birth or by young infants. This could potentially transform sickle-cell disease and beta-thalassemia -- life-threatening inherited anemias -- into benign or nearly benign conditions. The findings were published by the journal Science, in its online Science Express, on December 4.

After birth, babies gradually switch from producing fetal hemoglobin (HbF) to an adult form. From population studies, it's been known for many years that people who retain the ability to produce HbF have much milder forms of anemia. Attempts to develop therapies to reactivate HbF directly have been hampered by a lack of understanding of how HbF production is switched off. The drug hydroxyurea often raises HbF in patients, but responses are not uniform and there are potential side effects.

Seeking a better approach, researchers Stuart Orkin, MD, a Howard Hughes Medical Institute investigator at Children's Hospital Boston, and Vijay Sankaran, an MD-PhD student in Orkin's lab, in collaboration with researchers at the Broad Institute of Harvard and MIT, capitalized on comprehensive gene association studies that identified DNA sequence variants (altered strings of genetic code) that correlate with HbF levels. In a study published last July, they identified five variants that influence HbF levels and disease severity in a group of 1600 patients with sickle-cell disease, the most common inherited blood disorder in the United States.

The variant with the largest effect on HbF levels contains a gene called BCL11A. Located on chromosome 2, it encodes a transcription factor, a protein that regulates activity of other genes. This turned out to be a valuable lead.

In the new study, led by Orkin and Sankaran, the team showed that BCL11A directly suppresses HbF production. When the researchers suppressed BCL11A itself in human red-blood-cell precursors, the cells began making HbF in large amounts.

"This is one of very few instances in the gene association field where one has been able to take a candidate gene and figure out what it's doing," says Orkin, the study's senior investigator who is also a professor of pediatrics at Harvard Medical School and chair of pediatric oncology at Dana-Farber. "It's pretty clear that this gene is a silencer of fetal hemoglobin. If you could knock it down to a low level, you could turn on fetal hemoglobin."

"The discovery of a single gene that profoundly affects fetal hemoglobin levels represents a major breakthrough in the quest for effective therapies for sickle cell disease and thalassemia," notes Elizabeth G. Nabel, MD, director of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, which helped support the study. "Researchers can now direct their efforts at developing novel therapies aimed at a specific target that could dramatically alter the course of these often devastating blood disorders. This news should bring great hope to the millions of people worldwide affected by sickle cell disease and thalassemia."

Increasing levels of HbF would compensate for abnormal or insufficient adult hemoglobin in sickle-cell anemia or thalassemia, easing symptoms and in some cases achieving a virtual cure, the researchers say. The drug hydroxyurea, used in some patients with hemoglobin disorders, often raises HbF levels, but the increases are modest, it doesn't work in all patients, it can cause toxicity, and no one knows how it works.

"While it's been demonstrated that increased levels of HbF ameliorate the severity of sickle cell disease and beta-thalassemia, no direct strategies have yet been developed to increase HbF in these diseases," says Sankaran. "By reducing BCL11A expression or activity, we may be able to develop targeted therapies."

Hemoglobin is the protein in red blood cells that carries oxygen to the body's tissues. In sickle- cell disease, hemoglobin is abnormal, forming long chains that make red blood cells stiff and sickle-shaped. In thalassemia, the body's ability to produce hemoglobin is severely compromised. The hallmark of both disorders is anemia that can range from mild to life-threatening. Sickle-cell disease can cause severe pain and eventual organ damage as the abnormal, sickle-shaped cells block blood vessels, robbing tissues of their blood supply; beta-thalassemia requires frequent blood transfusions and then chelation therapy to rid the blood of excess iron that also leads to organ failure.

At birth, HbF comprises between 50 to 95 percent of a child's hemoglobin before the switch to adult hemoglobin production. The fetal form is thought to be an adaptation to the low oxygen in the fetal environment. Fetal hemoglobin has a higher affinity for oxygen, enabling it to pull oxygen more easily from the mother's circulation.

Are there potential side effects from boosting fetal hemoglobin levels? No, the researchers say. "Some people with rare genetic deletions have 100 percent fetal hemoglobin, and they're perfectly normal," says Orkin.

Orkin and Sankaran are conducting further studies to figure out how the switch from fetal to adult hemoglobin production occurs and how to target BCL11A therapeutically. "Improved understanding will permit the design of therapies for reactivation of HbF in patients with sickle-cell disease or thalassemia," says Orkin.

This study was supported by grants from the National Heart, Lung and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Howard Hughes Medical Institute.

Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 500 scientists, including eight members of the National Academy of Sciences, 11 members of the Institute of Medicine and 13 members of the Howard Hughes Medical Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital Boston today is a 397-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital and its research visit:

CONTACT: Rob Graham


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. N.J. Hospitals, Military and Veterans Affairs Join Broad Effort to Improve Returning Vets Healthcare
2. Turning Clocks Back Increases Risk of Drowsy Driving
3. With the Economy of the United States at a Turning Point, Health Care Could Be Our Next Serious Crisis ...
4. Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging
5. Drinking Problems Greater Among Returning Combat Veterans
6. Turning Life Insurance to Cash
7. Karen Haney Joins The Turning Point Group as Partner and Vice President of Client Services - Healthcare
8. Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans
9. RAI CEO: Returning Value in a Challenging Time
10. Courage Center Offers Credentialed Educational Forum on Issues of Returning Injured Employees to Work
11. Chehalis Tribes Announce Benefit to Help Returning Combat Veterans
Post Your Comments:
Related Image:
Turning back the Clock in Inherited Anemias
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: